XIAMEN AMOYTOP BIOTECH CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 59.85 CNY | +0.59% |
|
-8.44% | +14.33% |
| Apr. 22 | Xiamen Amoytop Biotech Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| Mar. 18 | China Stocks Advance Over Positive Economic Data; Amoytop Biotech Rises 6% | MT |
| Sales 2024 * | 2.81B 388M | Sales 2025 * | 3.69B 510M | Capitalization | 24.35B 3.36B |
|---|---|---|---|---|---|
| Net income 2024 * | 754M 104M | Net income 2025 * | 1.03B 143M | EV / Sales 2024 * | 8.66 x |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 6.59 x |
| P/E ratio 2024 * |
32.3
x | P/E ratio 2025 * |
23.6
x | Employees | 1,960 |
| Yield 2024 * |
0.21% | Yield 2025 * |
0.62% | Free-Float | 31.48% |
More Fundamentals
* Assessed data
More news
| 1 day | +0.59% | ||
| 1 week | -8.44% | ||
| Current month | -3.39% | ||
| 1 month | -8.79% | ||
| 3 months | +11.33% | ||
| 6 months | +40.16% | ||
| Current year | +14.33% |
1 week
57.58
66.26
1 month
57.5867.89
Current year
47.3569.97
1 year
31.0169.97
3 years
21.3269.97
5 years
21.3281.50
10 years
21.3281.50
| Managers | Title | Age | Since |
|---|---|---|---|
Li Sun
CEO | Chief Executive Officer | 58 | 13-04-30 |
Yi Ling Yang
DFI | Director of Finance/CFO | 49 | 97-06-30 |
Shi Yuan Wang
CTO | Chief Tech/Sci/R&D Officer | 51 | 00-08-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Feng Qin Li
BRD | Director/Board Member | 64 | 13-05-31 |
Chun Lan
BRD | Director/Board Member | 58 | 00-03-31 |
Li Sun
CEO | Chief Executive Officer | 58 | 13-04-30 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 34 M€ | +2.35% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-24 | 59.85 | +0.59% | 2,635,627 |
| 24-04-23 | 59.5 | -7.99% | 5,136,224 |
| 24-04-22 | 64.67 | +3.19% | 2,477,567 |
| 24-04-19 | 62.67 | -5.55% | 2,659,078 |
| 24-04-18 | 66.35 | +1.50% | 1,792,316 |
End-of-day quote Shanghai S.E., April 23, 2024
More quotes
XIAMEN AMOYTOP BIOTECH CO., LTD is a China-based company mainly engaged in the biopharmaceutical business, including the research, development, manufacture and sales of recombinant proteins and their long-acting modified drugs. The Company's main research and development direction is immune-related cytokine drugs, focusing on systemic immune solutions based on cytokine drugs, and its products mainly include Peginterferon alfa-2b Injection, rhGM-CSF (Recombinant Human Granulocyte/Macrophage Colony-Stimulating Factor for Injection), rHuG-CSF (Recombinant Human Granulocyte-Colony Stimulating Factor for Injection) and Recombinant Human Interleukin-11 for Injection. The Company distributes its products within domestic market and to overseas markets.
Sector
Pharmaceuticals
Calendar
2024-08-20
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
59.85
CNY
Average target price
89.2
CNY
Spread / Average Target
+49.04%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +14.33% | 3.34B | |
| -2.86% | 87.37B | |
| +3.95% | 41.01B | |
| -21.94% | 28.08B | |
| +53.11% | 24.72B | |
| -5.41% | 17.47B | |
| -44.23% | 11.69B | |
| -17.60% | 11.6B | |
| -13.96% | 11.56B | |
| -0.22% | 8.44B |
- Stock Market
- Equities
- 688278 Stock
